NuSep (NSP) wishes to advise the market that it has signed a new three year Gels distribution agreement with Thermo Fisher Scientific. This agreement has a minimum guaranteed purchases commitment of US$850,000 over the first 15 months. This distribution agreement will provide access to NuSep’s nUView gels in the Bio-Rad and Invitrogen format cassettes which account for approximately 90% of all the gels sold in the US. The minimum purchases amount of $850,000 over the first 15 months represents a doubling of NuSep’s Gel sales over the last financial year.
Dr Hari Nair, Managing Director of NuSep said that “This is a significant distribution agreement for NuSep as it strengthens our relationship with one of the world’s premier Life Science companies and gives us worldwide reach for our Gel products”. Mr John Manusu, NuSep’s Executive Chairman said, “Global distribution agreements like this establish the framework which will enable NuSep to achieve its goal of a 10% market share of the Gels market. “
NuSep (NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from Fraction to Function. The company has offices in both Sydney Australia and Atlanta, USA. With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.
http://www.traderdealer.com.au/fundamentals/nsp
